Company profile for Cytora Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Cytora is a clinical stage stem cell company developing a new class of medicines based on a novel and transformative patented platform stem cell technology derived from unique human Oral Mucosa Stem Cells (hOMSC). Cytora has developed a revolutionary patent protected technology platform to produce “off the shelf” (allogeneic) therapeutic doses of hOMSC to treat some of the most challenging diseases of this decade includin...
Cytora is a clinical stage stem cell company developing a new class of medicines based on a novel and transformative patented platform stem cell technology derived from unique human Oral Mucosa Stem Cells (hOMSC). Cytora has developed a revolutionary patent protected technology platform to produce “off the shelf” (allogeneic) therapeutic doses of hOMSC to treat some of the most challenging diseases of this decade including chronic wounds such as incurable diabetic foot ulcers (IDFU) and degenerative diseases such as Parkinson's Disease, Multiple System Atrophy (MSA), and Alzheimer’s Disease.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Israel
Address
Address
Hayozma Street , Colab Square, Yokneam
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

AMWC Asia-TDAC

AMWC Asia-TDAC

Not Confirmed

envelop Contact Supplier

AMWC Asia-TDAC

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.pharmiweb.com/press-release/2026-01-07/cytora-therapeutics-made-scientific-and-zeo-scientifix-announce-partnership-to-manufacture-and-com

PHARMIWEB
07 Jan 2026

https://www.prnewswire.com/news-releases/cytora-reports-phase-1-data-of-stem-cell-treatment-for-multiple-system-atrophy-302458811.html

PR NEWSWIRE
19 May 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty